We propose a mechanistic framework where natriuresis induced by SGLT2 inhibition, RAAS blockade with telmisartan, and moderate sodium restriction drains this compartment, restores adipose insulin signaling, and allows for stable ∼1kg per week fat loss. This review synthesizes human and preclinical evidence and provides a prognosis model.

1. Introduction  

   
   

Obesity associated with hypertension frequently displays “salt-sensitivity”: disproportionate BP and weight gain with high sodium intake. The classical explanation is volume expansion. The Titze model adds a second compartment: sodium bound to glycosaminoglycans in interstitium without obligate water retention. This compartment is expanded in obesity and hypertension and correlates with local inflammation.

2.Mechanisms

2.1 Non-osmotic sodium storage in adipose tissue

23Na-MRI studies demonstrate that excess dietary Na+ accumulates in skin and muscle interstitium. In adipose, high Na+ activates macrophages via TonEBP/NFAT5, increasing TNFα, IL-6 and reducing adiponectin. The result is localized insulin resistance independent of total body water.

2.2 SGLT2 inhibition: osmotic + tubular natriuresis

SGLT2 inhibitors block proximal glucose and sodium reabsorption. This causes ∼70g/day glucosuria and ∼400-500mL ECF contraction in week 1. 

Importantly, SGLT2i also reduce adipose tissue macrophage infiltration independent of glycemia, suggesting direct anti-inflammatory effects.

2.3 Telmisartan: RAAS blockade + PPARγ modulation 

As an ARB, telmisartan increases natriuresis via aldosterone suppression. Uniquely, it is a partial PPARγ agonist. PPARγ activation improves adipocyte differentiation, increases adiponectin, and reduces adipose inflammation. This complements natriuresis by improving the metabolic quality of fat during sodium depletion.

2.4 Low sodium diet: < 5g NaCl / day

Moderate sodium restriction prevents refilling of the interstitial sodium pool. Human RCTs show 6g/day additional salt reduces insulin sensitivity by 20-25% in 7 days without BP change. Combined with ARB, this accelerates net sodium efflux from tissue.

3. Integrated model: Drain, then Deficit

Phase 1, Weeks 1-3: Natriuresis. Interstitial Na leaves adipose. Markers: -2 to -3kg weight, -3 to -4cm waist, -10 to -15mmHg SBP, reduced edema. This is not fat loss but removes the inflammatory brake on lipolysis. 

Phase 2, Weeks 4+: True fat loss. With insulin signaling restored, a ∼1000 kcal/day deficit yields ∼1kg/week. SGLT2i provides ∼280 kcal/day of the deficit via glucosuria. Remaining deficit comes from diet and activity. Protein 1.2-1.6g/kg and resistance training 2-3x/week preserve RMR and lean mass.

4. Prognosis for weight loss

Based on the above mechanisms, expected trajectory:  

• Week 1-2: -2 to -3kg. Mostly water + sodium from interstitium.  

• Week 3-12: -0.8 to -1.2kg/week. Depends on adherence to deficit. Plateau risk at week 6-8 due to 10-15% RMR adaptation.  

• Month 3-6: -5 to -8kg total fat if deficit maintained.  

Sustainability factors: 

1. Electrolyte monitoring at 2 weeks due to ARB + low Na hyperkalemia risk. 

   
   

2. Preventing metabolic adaptation with protein + resistance training. 

   
   

3. Maintaining <5g Na to avoid refilling interstitial stores.

5. Clinical implications and limitations  

This framework does not replace caloric deficit but explains why some patients fail to lose fat despite deficit: adipose inflammation from sodium storage. The combination of SGLT2i + ARB + moderate Na restriction is already guideline-supported for HF and CKD.

Limitations: Human data directly linking interstitial Na depletion to fat loss are correlative. Long-term safety of <5g Na with ARB needs K monitoring. 

Animal Studies : High Tissue Sodium Blocks Lipolysis (Fat Burning)

When animals are fed high-salt diets, sodium pools in the interstitial spaces of skin, muscle, and adipose tissue, altering how fat tissue functions. [1, 2]

Hypertrophy over Lipolysis: In rodent models (such as Wistar rats), chronic high-sodium diets induce adipocyte hypertrophy (enlargement of fat cells) and significantly increase overall white adipose tissue mass.

The Cellular Brake: In vitro and in vivo animal tissue tests show that high extracellular sodium concentrations upregulate adipogenesis (the creation of new fat cells). This shifts the tissue's state toward fat storage rather than lipolysis (fat breakdown), trapping energy inside the cells

6. Conclusion

Natriuresis may be more than a hemodynamic tool. By draining sodium from adipose interstitium, SGLT2i + telmisartan + sodium restriction may restore insulin signaling and enable predictable, stable fat loss of ∼1kg/week. Future studies should use 23Na-MRI and clamp studies to test this   drain then deficit   hypothesis.

References: 

Titze (2009, 2014): Dr. Jens Titze is the pioneer of non-osmotic sodium storage. His work proved that sodium accumulates in the interstitium of the skin and muscles bound to glycosaminoglycans (GAGs), completely challenging the old dogma that sodium only exists in a strict water-equilibrated state. [1, 2, 3]

Benson (2004): This refers to a landmark study by Benson et al. establishing that Telmisartan acts as a unique partial agonist of PPAR-γ (peroxisome proliferator-activated receptor gamma), which directly promotes adipocyte remodeling, reduces inflammation, and improves insulin signaling. [1, 2]

SGLT2i Tissue Sodium Clearance (Hernandez 2020 / Oliveras 2020 / Chilton 2015 / Xu 2017): Multiple teams have confirmed that SGLT2 inhibitors (like dapagliflozin) actively reduce tissue sodium content(measured using non-invasive \(^{23}\text{Na-MRI}\)). By promoting natriuresis, they pull sodium out of the interstitial tissue reservoirs. [1, 2, 3]